France | Odysséa

Odysséa is the fruit of a friendship, associated with a common idea and will, of three women of heart.

In 2002, Frédérique Quentin and Frédérique Jules decided to create a solidarity sports challenge against breast cancer: this is the beginning of the Odysséa adventure. This high-level athlete who was part of the French athletics team, and this physiotherapist from the world of sport, also a former athlete, were quickly joined by Anne Bergougnoux, who currently heads the association and whose communication is the job.

Together, the trio wasted no time and launched Odysséa with a first edition in Paris, in 2002, bringing together 1000 women at the foot of the Eiffel Tower. The operation will have made it possible to donate 10,000 € in favor of research against breast cancer, all the volunteers are friends and family members.

For 20 years now, the story has continued and continues to grow, always keeping the same momentum of solidarity, sharing, conviviality and pink.

Odysséa supports Gustave Roussy's COMPASS project

In 2021 Odysséa was able to participate in the financing of Gustave Roussy's COMPASS [1] project.  COMPASS aims to identify new therapeutic strategies for a very harmful type of breast cancer: triple-negative cancer.
Odysséa supports Gustave Roussy's COMPASS project

Triple-negative cancer unfortunately remains a difficult cancer to treat, with a high risk of relapse and a very limited number of effective therapies.  Triple-negative cancer is characterized by the absence of expression of estrogen and progesterone hormone receptors and the absence of overexpression of HER-2 growth factor.

In numbers, triple-negative cancer is:

  • 15% of breast cancer cases, i.e. 7,500 women affected each year in France and 140,000 women worldwide.
  • 40% of affected women under the age of 40.
  • 1.200 women in France face early treatment failure

 

With his COMPASS project, Gustave Roussy is committed to identifying new effective therapeutic strategies for women with triple-negative breast cancer.  Led by Dr. Barbara Pistilli, COMPASS aims to determine over the next 3 years the most effective potential strategies in the treatment of early relapses of triple-negative breast cancer. Approximately 200 patients will be included in the COMPASS program over 3 years.

The 3-year program:

  • 2022: Identify a combination of bispecific antibodies or conjugated antibodies and immunotherapy that could improve survival.
  • 2023 : Study combinations with CAR-T cells, an innovative strategy already used in other cancers such as lymphomas.
  • 2024: Identify biomarkers predictive of early relapse.
Social
Website